TG8-260
Catalog No.
BA5737
TG8-260 is a second-generation antagonist developed to attenuate inflammation-driven pathology in central nervous system and peripheral diseases.
Featured Products
TG8-260 is a second-generation antagonist developed to attenuate inflammation-driven pathology in CNS and peripheral disorders.TG8-260 reduces neuroinflammation and gliosis in the hippocampal region of the rat following pilocarpine-induced sustained status epilepticus.Pharmacokinetic data for TG8-260 show a plasma half-life of 2.14 hours and an oral bioavailability of 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting receptor-mediated expression of inflammatory genes in BV2-h microglia, making it suitable for the study of anti-inflammatory pathways in animal models of peripheral inflammatory diseases.
| Physical Appearance | A solid |
| Storage | -20°C |
| M.Wt | 344.41 |
| Cas No. | 2490544-50-6 |
| Formula | C21H20N4O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |